Douglas J. Manion - Aug 1, 2023 Form 4 Insider Report for Aclaris Therapeutics, Inc. (ACRS)

Role: Pres and CEO, Director
Signature: /s/ Mark Ballantyne, Attorney-in-Fact
Stock symbol: ACRS
Transactions as of: Aug 1, 2023
Transactions value $: -$43,527
Form type: 4
Date filed: 8/3/2023, 04:24 PM
Previous filing: Mar 17, 2023
Next filing: Jan 3, 2024

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ACRS	Common Stock	Options Exercise		+15.6K	+121.68%		28.4K	Aug 1, 2023	Direct	F1
transaction	ACRS	Common Stock	Tax liability	-$43.5K	-4.44K	-15.64%	$9.81	23.9K	Aug 1, 2023	Direct	F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ACRS	Restricted Stock Units	Options Exercise	$0	-15.6K	-25%	$0.00	46.7K	Aug 1, 2023	Common Stock	15.6K		Direct	F1, F3

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	Each restricted stock unit represents a contingent right to receive one share of common stock of the issuer.
F2	The transaction reported represents the withholding of shares by the issuer to satisfy the Reporting Person's tax withholding obligations in connection with the vesting and settlement of restricted stock units described in this Form 4.
F3	The shares underlying these restricted stock units vest in four equal annual installments beginning on August 1, 2023, subject to the Reporting Person's continuous service with the Issuer as of the applicable vesting date.